source
- FDA approves Regeneron's siRNA drug Livsayis for myasthenia gravis, expanding its neurology portfolioRegeneron has received FDA clearance for its siRNA‑based therapy cemdisiran, now marketed as Livsayis, to treat myasthenia gravis. This approval is the second new myasthenia gravis drug cleared by…
- nChroma Bio cuts workforce by half and stops HBV cure trialnChroma Bio, a Boston biotech focused on epigenetic therapies, announced it is reducing its staff by roughly half. The reduction follows the decision to halt enrollment in its phase 1/2 study of C…